AU2020341926B2 - Therapeutic or prophylactic method for diabetes using combination medicine - Google Patents

Therapeutic or prophylactic method for diabetes using combination medicine

Info

Publication number
AU2020341926B2
AU2020341926B2 AU2020341926A AU2020341926A AU2020341926B2 AU 2020341926 B2 AU2020341926 B2 AU 2020341926B2 AU 2020341926 A AU2020341926 A AU 2020341926A AU 2020341926 A AU2020341926 A AU 2020341926A AU 2020341926 B2 AU2020341926 B2 AU 2020341926B2
Authority
AU
Australia
Prior art keywords
compound
acid
solvent
formula
solvents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020341926A
Other languages
English (en)
Other versions
AU2020341926A1 (en
Inventor
Sohei KATSUMI
Yasuko Mera
Seiya MOCHIDA
Chihiro Okuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2020341926A1 publication Critical patent/AU2020341926A1/en
Application granted granted Critical
Publication of AU2020341926B2 publication Critical patent/AU2020341926B2/en
Assigned to SHIONOGI & CO., LTD. reassignment SHIONOGI & CO., LTD. Amend patent request/document other than specification (104) Assignors: JAPAN TOBACCO INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020341926A 2019-09-04 2020-09-03 Therapeutic or prophylactic method for diabetes using combination medicine Active AU2020341926B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-161526 2019-09-04
JP2019161526 2019-09-04
PCT/JP2020/033463 WO2021045159A1 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法

Publications (2)

Publication Number Publication Date
AU2020341926A1 AU2020341926A1 (en) 2022-03-17
AU2020341926B2 true AU2020341926B2 (en) 2026-02-26

Family

ID=74852211

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020341926A Active AU2020341926B2 (en) 2019-09-04 2020-09-03 Therapeutic or prophylactic method for diabetes using combination medicine

Country Status (10)

Country Link
US (1) US20230119894A1 (https=)
EP (2) EP4026564A4 (https=)
JP (2) JP7692832B2 (https=)
KR (1) KR20220056219A (https=)
CN (2) CN119113123A (https=)
AU (1) AU2020341926B2 (https=)
BR (1) BR112022003323A2 (https=)
CA (1) CA3151909A1 (https=)
MX (1) MX2022002683A (https=)
WO (1) WO2021045159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
CA3175131A1 (en) * 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure
AU2022340358A1 (en) * 2021-09-02 2024-01-04 Daewoong Therapeutics Inc. Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
WO2025245592A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002011A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
WO2011109333A1 (en) * 2010-03-02 2011-09-09 Lexicon Pharmaceuticals, Inc. 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients
US20130085132A1 (en) * 2011-08-31 2013-04-04 Japan Tobacco Inc. Pyrazole compound and pharmaceutical use thereof
WO2013169546A1 (en) * 2012-05-10 2013-11-14 Eli Lilly And Company Pyrazole compounds as sglt1 inhibitors
WO2019144864A1 (en) * 2018-01-23 2019-08-01 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivative and use thereof
WO2019168096A1 (ja) * 2018-03-01 2019-09-06 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
CA3175131A1 (en) * 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002011A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
WO2011109333A1 (en) * 2010-03-02 2011-09-09 Lexicon Pharmaceuticals, Inc. 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients
US20130085132A1 (en) * 2011-08-31 2013-04-04 Japan Tobacco Inc. Pyrazole compound and pharmaceutical use thereof
WO2013169546A1 (en) * 2012-05-10 2013-11-14 Eli Lilly And Company Pyrazole compounds as sglt1 inhibitors
WO2019144864A1 (en) * 2018-01-23 2019-08-01 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivative and use thereof
WO2019168096A1 (ja) * 2018-03-01 2019-09-06 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Also Published As

Publication number Publication date
BR112022003323A2 (pt) 2022-05-24
US20230119894A1 (en) 2023-04-20
AU2020341926A1 (en) 2022-03-17
EP4342466A1 (en) 2024-03-27
EP4026564A1 (en) 2022-07-13
KR20220056219A (ko) 2022-05-04
JP2025094217A (ja) 2025-06-24
JPWO2021045159A1 (https=) 2021-03-11
JP7692832B2 (ja) 2025-06-16
MX2022002683A (es) 2022-04-07
CA3151909A1 (en) 2021-03-11
WO2021045159A1 (ja) 2021-03-11
EP4026564A4 (en) 2023-03-15
CN114585387B (zh) 2024-10-29
CN114585387A (zh) 2022-06-03
CN119113123A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
AU2020341926B2 (en) Therapeutic or prophylactic method for diabetes using combination medicine
AU2019249560B2 (en) Heteroaryl-substituted pyrazole compound and medicinal use thereof
AU2019227770B2 (en) Methyllactam ring compound and medicinal use thereof
AU8713998A (en) Amide derivative
UA120346C2 (uk) Амідні сполуки для лікування віл
WO2023088385A1 (zh) 用于egfr蛋白降解的化合物及其用途
CN116082312A (zh) 用作cdk7激酶抑制剂的化合物及其应用
AU2020343585B2 (en) Chronic kidney disease treatment or prevention method
RU2857384C2 (ru) Способ лечения или профилактики диабета с помощью комбинированной медицины
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
HK40068410A (en) Chronic kidney disease treatment or prevention method
RU2805312C2 (ru) Пиразольные соединения, замещенные гетероарилом, и их применение в фармацевтике
CN118591532A (zh) 用作cdk7激酶抑制剂的化合物及其应用
HK40044833A (en) Methyllactam ring compound and medicinal use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SHIONOGI & CO., LTD.

Free format text: FORMER NAME(S): JAPAN TOBACCO INC.